- Home
- FLYE vs APRE Comparison
FLYE vs APRE Comparison
Compare FLYE & APRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FLYE
- APRE
- Stock Information
- Founded
- FLYE 2018
- APRE 2006
- Country
- FLYE United States
- APRE United States
- Employees
- FLYE N/A
- APRE N/A
- Industry
- FLYE Aerospace
- APRE Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- FLYE Industrials
- APRE Health Care
- Exchange
- FLYE Nasdaq
- APRE Nasdaq
- Market Cap
- FLYE 16.9M
- APRE 15.8M
- IPO Year
- FLYE 2024
- APRE 2019
- Fundamental
- Price
- FLYE $0.60
- APRE $3.85
- Analyst Decision
- FLYE
- APRE Strong Buy
- Analyst Count
- FLYE 0
- APRE 2
- Target Price
- FLYE N/A
- APRE $15.50
- AVG Volume (30 Days)
- FLYE 4.9M
- APRE 33.0K
- Earning Date
- FLYE 02-10-2025
- APRE 11-07-2024
- Dividend Yield
- FLYE N/A
- APRE N/A
- EPS Growth
- FLYE N/A
- APRE N/A
- EPS
- FLYE N/A
- APRE N/A
- Revenue
- FLYE $30,297,313.00
- APRE $1,310,839.00
- Revenue This Year
- FLYE N/A
- APRE $134.21
- Revenue Next Year
- FLYE N/A
- APRE N/A
- P/E Ratio
- FLYE N/A
- APRE N/A
- Revenue Growth
- FLYE 14.77
- APRE 130.31
- 52 Week Low
- FLYE $0.38
- APRE $2.15
- 52 Week High
- FLYE $7.62
- APRE $8.85
- Technical
- Relative Strength Index (RSI)
- FLYE N/A
- APRE 56.63
- Support Level
- FLYE N/A
- APRE $3.34
- Resistance Level
- FLYE N/A
- APRE $3.83
- Average True Range (ATR)
- FLYE 0.00
- APRE 0.42
- MACD
- FLYE 0.00
- APRE 0.01
- Stochastic Oscillator
- FLYE 0.00
- APRE 36.04
About FLYE Fly-E Group Inc. Common Stock
Fly-E Group Inc is an electric vehicle company that is principally engaged in designing, installing and selling smart electric motorcycles, electric bikes, electric scooters and related accessories under the brand Fly E-Bike. It also provides connectivity solutions and value-added services to their customers.
About APRE Aprea Therapeutics Inc. Common stock
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline product is ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.